Skip to main content
. 2020 Nov 24;11(7):2059–2069. doi: 10.1016/j.apsb.2020.11.014

Figure 4.

Figure 4

tTF-AS1411 induces intratumoral thrombosis and reduces blood perfusion. (A) The gross appearance of MHCC-97H liver tumors 10 h after the first intravenous administration of tTF-AS1411 or controls into the mice. Significant bruising was observed in the tTF-AS1411 group, indicating blood pooling due to vascular occlusion, n = 3. (B) Near infrared reflection (NIR) imaging was performed on MHCC-97H tumor-bearing mice after administering Angio-Sense 680EX imaging agent, with pre-treatment of tTF-AS1411, n = 3. (C) Quantitative analysis of the AngioSense 680EX signal intensities in tumors. Error bars represent the mean ± SD, n = 3, ∗∗∗P < 0.01. (D) Representative images of MHCC-97H liver tumors from mice treated with Evans blue (5%) after pre-treatment with tTF-AS1411 or controls. Evans blue accumulation was significantly decreased in the tTF-AS1411 pre-treated tumors, n = 3. (E) Quantification of Evans blue contents in different tumors. Error bars represent the mean ± SD; ∗∗∗P < 0.001.